StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.19+0.01 (+7.37%)

Close on Nov 17, 2026Market cap $19.43MP/E –Yield –

IGC Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

IGC Pharma's operating cash flow for the twelve months ending Mar 31, 2026 was -$5.94M. For fiscal 2025 it was -$4.80M. The highest annual figure on record is $564.85K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Mar 31, 2025-$4.80M–
FY2024Mar 31, 2024-$5.20M–
FY2023Mar 31, 2023-$7.05M–
FY2022Mar 31, 2022-$7.46M–
FY2021Mar 31, 2021-$10.80M–
FY2020Mar 31, 2020-$8.68M–
FY2019Mar 31, 2019-$3.33M–
FY2018Mar 31, 2018-$1.93M–
FY2017Mar 31, 2017-$1.39M–
FY2016Mar 31, 2016-$157.70K–
FY2015Mar 31, 2015-$2.58M–
FY2014Mar 31, 2014-$1.74M-408.4%
FY2013Mar 31, 2013$564.85K–
FY2012Mar 31, 2012-$5.02M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ1 2026Mar 31, 2026-$1.22M–
Q3 FY2026CQ4 2025Dec 31, 2025-$1.22M–
Q2 FY2026CQ3 2025Sep 30, 2025-$2.09M–
Q1 FY2026CQ2 2025Jun 30, 2025-$1.41M–
Q4 FY2025CQ1 2025Mar 31, 2025-$730.00K–
Q3 FY2025CQ4 2024Dec 31, 2024-$1.32M–
Q2 FY2025CQ3 2024Sep 30, 2024-$996.00K–
Q1 FY2025CQ2 2024Jun 30, 2024-$1.75M–
Q4 FY2024CQ1 2024Mar 31, 2024-$526.00K–
Q3 FY2024CQ4 2023Dec 31, 2023-$1.59M–
Q2 FY2024CQ3 2023Sep 30, 2023-$1.62M–
Q1 FY2024CQ2 2023Jun 30, 2023-$1.47M–
Q4 FY2023CQ1 2023Mar 31, 2023-$1.52M–
Q3 FY2023CQ4 2022Dec 31, 2022-$1.65M–
Q2 FY2023CQ3 2022Sep 30, 2022-$1.69M–
Q1 FY2023CQ2 2022Jun 30, 2022-$2.20M–
Q4 FY2022CQ1 2022Mar 31, 2022-$887.00K–
Q3 FY2022CQ4 2021Dec 31, 2021-$2.42M–
Q2 FY2022CQ3 2021Sep 30, 2021-$2.30M–
Q1 FY2022CQ2 2021Jun 30, 2021-$1.85M–
Q4 FY2021CQ1 2021Mar 31, 2021-$2.51M–
Q3 FY2021CQ4 2020Dec 31, 2020-$1.85M–
Q2 FY2021CQ3 2020Sep 30, 2020-$2.46M–
Q1 FY2021CQ2 2020Jun 30, 2020-$3.99M–
Q4 FY2020CQ1 2020Mar 31, 2020-$1.99M–
Q3 FY2020CQ4 2019Dec 31, 2019-$2.24M–
Q2 FY2020CQ3 2019Sep 30, 2019-$1.57M–
Q1 FY2020CQ2 2019Jun 30, 2019-$2.87M–
Q4 FY2019CQ1 2019Mar 31, 2019-$1.15M–
Q3 FY2019CQ4 2018Dec 31, 2018-$1.33M–
Q2 FY2019CQ3 2018Sep 30, 2018-$316.00K–
Q1 FY2019CQ2 2018Jun 30, 2018-$535.00K–
Q4 FY2018CQ1 2018Mar 31, 2018-$958.00K–
Q3 FY2018CQ4 2017Dec 31, 2017-$346.00K-278.7%
Q2 FY2018CQ3 2017Sep 30, 2017-$105.07K–
Q1 FY2018CQ2 2017Jun 30, 2017-$521.93K–
Q4 FY2017CQ1 2017Mar 31, 2017-$908.01K–
Q3 FY2017CQ4 2016Dec 31, 2016$193.66K–
Q2 FY2017CQ3 2016Sep 30, 2016-$879.64K–

More IGC Pharma figures

See a number that looks wrong?